Robotic Nephroureterectomy

Nephroureterectomy removes the kidney, the full length of the ureter, and a cuff of bladder at the ureteric opening. It is the standard surgical treatment for upper tract urothelial carcinoma — cancer arising in the lining of the renal pelvis or ureter.

Upper tract urothelial carcinoma is less common than bladder cancer but shares the same cell type and behaviour. It tends to be multifocal and has a meaningful risk of recurrence in the bladder after surgery, which is why surveillance cystoscopy forms part of the standard follow-up plan.

Robotic assistance is used for nephroureterectomy at this practice. The operation involves working in two anatomical areas — the upper retroperitoneum around the kidney and the lower pelvis around the ureter and bladder — and robotic instrumentation can be helpful for precise dissection in both. The approach is determined by individual patient and tumour factors.

For a broader overview of kidney and upper tract cancer, see Kidney Cancer.

When is nephroureterectomy recommended?

The central judgement in upper tract urothelial carcinoma is whether the tumour can be safely managed endoscopically or whether the kidney and ureter need to come out. That decision is driven by grade, invasiveness, tumour location, multifocality, and the functional status of the affected kidney.

For most patients with high-grade or invasive disease, nephroureterectomy is the appropriate operation. High-grade upper tract tumours carry a meaningful risk of progression and are not reliably controlled with endoscopic approaches alone — attempting to preserve the kidney in this setting trades short-term functional benefit for a real oncological risk.

In carefully selected patients with low-risk disease — particularly those with a single functioning kidney or significantly compromised renal function — endoscopic management through ureteroscopy and laser treatment may be a reasonable alternative. This applies to a minority of cases, requires careful patient selection, and involves close surveillance to detect recurrence early. Where endoscopic management has been tried and failed, or is not appropriate given disease characteristics, nephroureterectomy is the recommended approach.

The consultation is where that decision is worked through — based on the imaging, the biopsy, and what the specific tumour profile suggests about the risk of progression.

The procedure

Robotic nephroureterectomy is performed under general anaesthesia. The kidney and ureter are removed in continuity — the full length of the ureter down to the bladder, with a small cuff of bladder wall at the ureteric insertion. This is essential for oncological completeness; leaving any ureteric stump risks disease recurrence in the remnant.

The procedure is performed through keyhole incisions. An assistant surgeon is present at the bedside throughout. A urinary catheter is placed during surgery and remains in place for several days while the bladder heals at the cuff closure site.

Operating time varies with anatomy and tumour complexity. Hospital stay is typically two to four days.

Recovery

Most patients are mobile within a day or two of surgery. The urinary catheter is removed once the bladder repair has healed, usually within five to seven days. Return to desk work is typically possible within two to three weeks. Strenuous activity is restricted for six weeks.

Follow-up and surveillance

Follow-up after nephroureterectomy has two components. First, surveillance of the remaining urinary tract — particularly the bladder — for recurrence. Bladder recurrence after upper tract urothelial carcinoma is well documented and occurs in a meaningful proportion of patients, which is why cystoscopy forms part of the standard post-operative surveillance plan. Second, monitoring of remaining kidney function through regular blood tests.

The frequency and duration of surveillance is guided by tumour pathology and will be discussed and planned before you leave hospital.

Risks and considerations

Nephroureterectomy carries the standard risks of major surgery — bleeding, infection, injury to surrounding structures, blood clots, and anaesthetic risks. Specific considerations include bladder recurrence (addressed through surveillance) and long-term reliance on one kidney. These risks will be discussed fully at your consultation.

If you have been diagnosed with upper tract urothelial carcinoma and want to understand your surgical options, contact the rooms to arrange a consultation. For more on kidney and upper tract cancer, see Kidney Cancer.

Clinical note: This page provides general information and is not a substitute for individual medical advice. Treatment decisions should be based on personalised assessment and discussion of options.

Last reviewed: April 2026